Cash flow generation remains inconsistent, evidenced by a 2026Q2 net loss of $183.0M that contrasts with $14.3M in operating cash flow, suggesting significant non-cash charges or accounting adjustments.
| Cash from Operations | 74.89M | 49.91M | 41.72M | 2.59M | -17.52M | -6.21M | 9.32M | 29.69M | 18.39M | 19.1M |
| Operating CF Margin % | - | 14.97% | 8.97% | 0.62% | -5.33% | -3% | 5.41% | 18.52% | 13.77% | 20.38% |
| Operating CF Growth % | 719.54% | 19.63% | 1511.45% | 114.78% | -182.24% | -166.6% | -68.62% | 61.5% | -3.74% | - |
| Net Income | -235.97M | -58.85M | 6.26M | 20.17M | -3.91M | -3.82M | 4.24M | -16.36M | -14.31M | -11.82M |
| Depreciation & Amortization | 20.3M | 22.18M | 21.3M | 19.39M | 9.19M | 6.26M | 4.73M | 4.83M | 4.37M | 4.61M |
| Stock-Based Compensation | 2.05M | 4.39M | 14.13M | 3.42M | 1.43M | 1.66M | 3.43M | -102.83K | 30K | 51.42K |
| Deferred Taxes | 3.41M | 1.27M | 3.78M | -1.07M | 17.97M | 14.35M | 2.21M | 6.99M | -10.93M | 0 |
| Other Non-Cash Items | 59.56M | 61.61M | 37.76M | 45.78M | 18.65M | 29.23M | 33.51M | 45.79M | 47.32M | -15.24M |
| Working Capital Changes | 55.32M | 19.3M | -41.51M | -85.11M | -60.85M | -53.88M | -38.8M | -11.44M | -8.09M | 41.51M |
| Change in Receivables | 37.61M | 24.58M | -51.65M | -56.87M | -24.97M | 1.99M | -21.74M | 41.49M | 17.32M | 33.49M |
| Change in Inventory | 28.21M | 34.91M | 14.18M | -11.07M | -55.31M | -34.5M | -5.31M | -8.64M | 10.36M | -2.25M |
| Change in Payables | -1.29M | -32.04M | 14.23M | -4.5M | 53.48M | -5.83M | 8.27M | -33.7M | -35.29M | 0 |
| Cash from Investing | -5.08M | -6.13M | -28.73M | -25.73M | 2.9M | -8.31M | -7.8M | -3.26M | -8.22M | -20.16M |
| Capital Expenditures | -3.29M | -5.64M | -9.79M | -22.56M | -9M | -13.92M | -4.5M | -3.45M | -5.71M | -1.39M |
| CapEx % of Revenue | 1.16% | 1.69% | 2.11% | 5.38% | 2.74% | 6.74% | 2.61% | 2.15% | 4.28% | 1.48% |
| Acquisitions | 261.41K | 390.38K | 37.51K | 4.37M | -3.49M | 253.92K | 51.15K | -129.34K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -6.2M | -8.97M | -12.66M | 137.36K | 5.12M | 309.81K | 0 | 317.95K | -2.51M | -18.77M |
| Cash from Financing | -78.11M | -50.71M | -10.06M | 32.95M | 14.82M | 7.36M | 33.53M | -26.95M | -10.46M | 2.33M |
| Debt Issued (Net) | -68.73M | -27.57M | 18.32M | 59.22M | 28.74M | 29.67M | 31.26M | -22.39M | -9.88M | 0 |
| Equity Issued (Net) | 488.29K | -926.9K | -734K | -3M | 0 | -3.5M | -30.91K | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -926.9K | -734K | -3M | 0 | -3.5M | -30.91K | 0 | 0 | 0 |
| Other Financing | -9.87M | -22.21M | -27.65M | -23.27M | -13.91M | -18.81M | 2.3M | -4.55M | -578.29K | 2.33M |
| Net Change in Cash | -18.11M | -11.78M | -3.66M | 14.65M | -2.57M | -6.48M | 39.07M | 1.24M | 535.63K | 1.39M |
| Free Cash Flow | 68.86M | 35.3M | 18.93M | -19.97M | -26.51M | -20.13M | 4.82M | 26.25M | 12.68M | 17.71M |
| FCF Margin % | 24.15% | 10.59% | 4.07% | -4.76% | -8.07% | -9.74% | 2.79% | 16.37% | 9.5% | 18.9% |
| FCF Growth % | 899.99% | 86.43% | 194.79% | 24.66% | -31.71% | -517.94% | -81.65% | 107% | -28.41% | - |
| FCF per Share | 1.08 | 0.56 | 0.30 | -0.32 | -0.63 | -0.51 | 0.13 | 0.86 | 0.45 | 0.63 |
| FCF Conversion (FCF/Net Income) | -0.29x | -0.96x | 12.86x | 0.14x | 2.43x | 0.90x | 2.77x | -1.62x | -1.67x | -1.62x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Argentine macroeconomic volatility exposure
According to quarterly financial filings, BIOX exhibits a persistent divergence between net income and operating cash flow, highlighted by a 2026Q2 net loss of $183.0M contrasted against $14.3M in positive operating cash flow, suggesting significant non-cash charges or accounting adjustments are masking underlying operational performance.
The consistent inability of net income to track with operating cash flow suggests that the company's reported earnings are heavily influenced by non-cash items, potentially related to hyperinflationary accounting or asset impairments. Investors should monitor whether this cash flow generation is sustainable or merely a byproduct of aggressive working capital management that may reverse in future periods.
As reported in recent financial statements, free cash flow has remained highly erratic, swinging from a $19.1M outflow in 2024Q3 to a $24.6M inflow in 2025Q4, indicating that the company's ability to self-fund its growth initiatives remains structurally inconsistent and highly sensitive to seasonal operational cycles.
The lack of a stable free cash flow trajectory suggests that the business model is currently struggling to achieve the scale necessary to cover its fixed cost base. This volatility implies that the company may remain reliant on external financing or capital markets to bridge the gap during periods of negative cash generation.
Based on the provided cash flow data, working capital changes have been a primary driver of liquidity fluctuations, with a significant $29.1M inflow in 2025Q4 followed by periods of substantial cash consumption, reflecting the inherent difficulty in managing inventory and receivables within the Argentine agricultural supply chain.
The wide swings in working capital suggest that the company's cash position is highly vulnerable to the timing of collections and inventory turnover. This instability warrants further investigation into whether the company is effectively managing its trade credit or if it is forced to absorb liquidity shocks to maintain its market position.
As indicated by the quarterly data, capital expenditures have remained modest, with the CapEx-to-revenue ratio peaking at 5.2% in 2024Q1 and declining to 0.3% by 2026Q2, suggesting that the company is currently prioritizing cash preservation over significant investment in physical infrastructure or capacity expansion.
The low capital intensity may imply that the company's primary growth engine, the HB4 technology, is not currently requiring heavy physical asset investment, or that management is deferring necessary maintenance. Investors should monitor whether this low level of spending is sufficient to support long-term competitive positioning in the agricultural inputs market.
Quick answers to the most common questions about buying BIOX stock.
Bioceres Crop Solutions Corp. (BIOX) generated $49.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Bioceres Crop Solutions Corp. (BIOX) generated $35.3M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Bioceres Crop Solutions Corp. (BIOX) spent $5.6M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Bioceres Crop Solutions Corp. (BIOX) spent $0.9M on share repurchases. This shows the company's commitment to returning capital to its equity investors.